NEPHROS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
NEPHROS, INC. (NEPH) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $49.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-03-15
- NEPHROS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $0.00.
- NEPHROS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $49.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $49.00K 10-K · filed 2024-03-15 | |
| 2022-09-30 | $49.00K 10-Q · filed 2022-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |